Xtant Medical Holdings, Inc.
XTNT evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $48.5M
- Lead Asset:
- hemoblast bellows
What it means
What to watch
Prepared research question
What matters most for XTNT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XTNT
Xtant Medical Holdings, Inc. (XTNT) is a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, with a portfolio of synthetic bone grafts, biologics, and surgical closure products.
Key risk: Sustained net losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$48.5M
Cash Runway
—
Lead Asset
hemoblast bellows
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Xtant Medical Holdings, Inc..
Xtant Medical Holdings, Inc. (XTNT) is a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, with a portfolio of synthetic bone grafts, biologics, and surgical closure products.
- Cash & equivalents of $9.9M as of 2026-06-30 [sec].
- Total revenue of $23.0M and net income of -$9.4M as of 2026-06-30 [sec].
- Shareholders' equity of $40.0M and total debt of $11.0M as of 2026-06-30 [sec].
- Completed sale of non-core Coflex, CoFix, and international hardware assets to Companion Spine for $21.4M in cash [news · published 2026-03-31].
- Commercial launches of nanOss Strata synthetic bone graft and CollagenX bovine collagen particulate product in 2025-2026 [news · published 2026-03-31].
What works
- Strengthened cash position to over $22 million after receiving amounts from the Companion Spine note receivable, while reducing term loan balance to $11.2 million [news · published 2026-03-31].
- Expanded product portfolio with next-generation synthetic bone graft (nanOss Strata) and new surgical closure product (CollagenX) [news · published 2026-03-31].
- Maintains extensive sales channel with independent agents, stocking distributors, and national accounts program providing access to major GPOs and IDNs [sec_mda · as of 2026-03-31].
What to weigh
- Net loss of -$9.4M as of 2026-06-30 indicates ongoing unprofitability [sec].
- Total debt of $11.0M as of 2026-06-30 represents a significant liability relative to cash reserves [sec].
- Reliance on non-core asset sales (e.g., Companion Spine transaction) to boost cash position suggests underlying operational cash flow challenges [news · published 2026-03-31].
From the filings
Quoted directly from source documents.
Cash position strengthened to over $22 million after Companion Spine transaction
“we have increased our current cash position to over $22 million while reducing our term loan balance to $11.2 million”
News · March 31, 2026
Commercial launch of nanOss Strata synthetic bone graft
“announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™”
News · March 31, 2026
Sale of non-core assets to Companion Spine for $21.4 million
“Completed the previously announced sale of Xtant's non-core Coflex® and CoFix assets and its international hardware businesses to Companion Spine for a total sale price of $21.4 million in cash”
News · March 31, 2026
Extensive sales channel with independent agents and national accounts
“have an extensive sales channel of independent commissioned agents and stocking distributors in the United States representing some or all of our products”
SEC MD&A · March 31, 2026
Risks & what to watch (3)›
Key risks
- Sustained net losses — Net income of -$9.4M as of 2026-06-30 indicates ongoing profitability challenges [sec].
- Debt-to-cash ratio — Total debt of $11.0M exceeds cash & equivalents of $9.9M as of 2026-06-30, creating liquidity risk [sec].
- Dependence on asset sales
What to watch
- Commercial adoption of newly launched nanOss Strata and CollagenX products [news · published 2026-03-31].
- Impact of expanded field sales force on revenue growth in 2026 [news · published 2026-03-31].
- Ability to reduce net losses and achieve profitability given current cash burn rate [sec].
- Integration and market performance of recently acquired HEMOBLAST Bellows distribution rights [news · published 2026-04-13].
Sources: Competitor trials · News · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Xtant Medical Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xtant Medical Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.99 · 0% dilution
No tracked pipeline phase
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 20, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 39,674
- Daily short volume (Jun 29, 2026)
- 39.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XTNT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xtant Medical Holdings, Inc.?
Xtant Medical Holdings, Inc. (XTNT) is a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, with a portfolio of synthetic bone grafts, biologics, and surgical closure products.
Who is the CEO of Xtant Medical Holdings, Inc.?
Mr. Sean E. Browne is the chief executive officer of Xtant Medical Holdings, Inc. (XTNT).
Where is Xtant Medical Holdings, Inc. headquartered?
Xtant Medical Holdings, Inc. (XTNT) is headquartered in Belgrade, MT, United States.
What therapeutic areas does Xtant Medical Holdings, Inc. focus on?
Xtant Medical Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.